Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Laharie

Showing results (11-20 of 209) with videos related to

Pageof 21
Sort By:
Alimentary Pharmacology & Therapeutics|December 19, 2019
Letter: should we intensify infliximab in acute severe ulcerative colitis?David Laharie, Pauline Rivière
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 25, 2018
ReplyDavid Laharie, Gauthier Pellet
Cancers|February 25, 2023
Management of Inflammatory Bowel Disease in Patients with Current or Past MalignancyFlorian Poullenot, David Laharie
Alimentary Pharmacology & Therapeutics|December 8, 2022
Editorial: selecting therapy for ulcerative colitis-think a step aheadDavid Laharie, Pauline Riviere
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 14, 2024
Controversies in medical vs surgical management of ileocecal crohn's diseaseLéon Maggiori, David Laharie
La Revue Du Praticien|February 3, 2015
[First line therapy of inflammatory bowel disease]Florian Poullenot, David Laharie
Alimentary Pharmacology & Therapeutics|September 11, 2025
Editorial: Ulcerative Colitis Management in the Biologic Era-Data From the English Healthcare DatabasesGuillaume Le Cosquer, David Laharie
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 12, 2025
Letter to Goodsall et alJean-Yves Mary, David Laharie
Journal of Crohn'S & Colitis|February 25, 2023
Should we Target Complete Endoscopic Healing in Patients with Acute Severe Ulcerative Colitis?David Laharie, Jean-Yves Mary
Alimentary Pharmacology & Therapeutics|July 19, 2025
Editorial: JAK to JAK-Navigating Intra-Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' ReplyMathieu Uzzan, David Laharie, Julien Kirchgesner
Pageof 21

Showing results (11-20 of 209) with videos related to

Sort By:
Pageof 21
Alimentary Pharmacology & Therapeutics|December 19, 2019
Letter: should we intensify infliximab in acute severe ulcerative colitis?David Laharie, Pauline Rivière
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 25, 2018
ReplyDavid Laharie, Gauthier Pellet
Cancers|February 25, 2023
Management of Inflammatory Bowel Disease in Patients with Current or Past MalignancyFlorian Poullenot, David Laharie
Alimentary Pharmacology & Therapeutics|December 8, 2022
Editorial: selecting therapy for ulcerative colitis-think a step aheadDavid Laharie, Pauline Riviere
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 14, 2024
Controversies in medical vs surgical management of ileocecal crohn's diseaseLéon Maggiori, David Laharie
La Revue Du Praticien|February 3, 2015
[First line therapy of inflammatory bowel disease]Florian Poullenot, David Laharie
Alimentary Pharmacology & Therapeutics|September 11, 2025
Editorial: Ulcerative Colitis Management in the Biologic Era-Data From the English Healthcare DatabasesGuillaume Le Cosquer, David Laharie
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 12, 2025
Letter to Goodsall et alJean-Yves Mary, David Laharie
Journal of Crohn'S & Colitis|February 25, 2023
Should we Target Complete Endoscopic Healing in Patients with Acute Severe Ulcerative Colitis?David Laharie, Jean-Yves Mary
Alimentary Pharmacology & Therapeutics|July 19, 2025
Editorial: JAK to JAK-Navigating Intra-Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' ReplyMathieu Uzzan, David Laharie, Julien Kirchgesner
Pageof 21